India's Clinical Trials Market Accelerates - There has been a perceptible change from skepticism to acceptance in how India is viewed for clinical trials. - BioPharm International

ADVERTISEMENT

India's Clinical Trials Market Accelerates
There has been a perceptible change from skepticism to acceptance in how India is viewed for clinical trials.


BioPharm International
Volume 21, Issue 5

REFERENCES

1. Anon. US wants FDA inspectors stationed in India. The Times of India. 2008; Mar 19. Available from: http://timesofindia.indiatimes.com/World/USA/US_wants_FDA_inspectors_stationed_in_India/articleshow/2880547.cms

2. Barnes K. FDA considering establishing Indian presence. Pharma Technologist. 2008. Available from: http://www.in-pharmatechnologist.com/news/ng.asp?n=82658-fda-india-china-inspection/

3. Leavitt M. Secretary Mike Leavitt's blog. Chennai, India. 2008; Jan 7. Available from: http://secretarysblog.hhs.gov/my_weblog/2008/01/chennai-india-w.html

4. Sahoo U, Kermani F. The contract research industry in India. In: Langer ES, editor. Advances in biopharmaceutical technology in India, 1st edition. Rockville, MD:BioPlan Associates, Inc. 2007. Available from: http://www.bioplanassociates.com/

5. Basu I. India's clinical trials and tribulations. The Asia Times. 2004. Available from: http://www.atimes.com/atimes/South_Asia/FG23Df03.html

6. Barnes K. What can CROs do to keep Indian clinical trials ethical? Pharma Technologist. 2006. Available from: http://www.in-pharmatechnologist.com/news/ng.asp?n=68154-chiltern-international-india-clinical-trial-cro/


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here